Lupus breakthrough 2019. The results are of an international, three-year, Phase 3 trial of a potential new drug that treats this autoimmune disease (also known as systemic lupus erythematosus (SLE)). Feb 6, 2024 · Researchers have worked out how to fix a defect that causes lupus, and hope their world-first discovery will offer effective long-term treatment. 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. Sep 17, 2019 · South San Francisco, CA -- September 17, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U. Both the classification criteria and management recommendation for SLE were updated. New promising medications have been widely developed and tested, although subsequent clinical studies are warranted. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva ®) for adults with lupus nephritis – the most common complication of lupus. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva® (obinutuzumab) for adults with lupus nephritis. Food and Drug Administration has granted Breakthrough Therapy Designation to Gazyva® for adults with lupus nephritis. Jan 28, 2026 · “The Lupus Research Alliance is dedicated to advancing lupus research, and today’s FDA Breakthrough Therapy designation for litifilimab reinforces our shared understanding of cutaneous lupus as a serious, debilitating condition that urgently needs therapies that can alter the course of the disease," said Albert T. Dec 27, 2023 · Advancements in measuring lupus activity In order to know if a drug is working, medical scientists and providers need dependable ways to measure the disease’s activity. Remarkably, this is only the second drug approved for Sep 3, 2024 · Breakthrough Research Targets a Safer Cure for Lupus By Office of the President | Sep 3, 2024 SUNY Downstate has long been at the forefront of advancing the diagnosis, treatment, and research of systemic lupus erythematosus (SLE), commonly known as lupus. This complex chronic autoimmune disease disproportionately affects women of color and can severely impact various organs, including the . In 2019, great progress in various aspects of SLE emerged. Lupus nephritis overwhelmingly impacts women, particularly young women of color. 5 million people in the U. Jul 10, 2024 · Scientists have discovered a molecular defect that promotes the pathologic immune response in lupus and demonstrated that reversing the defect may potentially reverse the disease. Dec 13, 2019 · When it comes to lupus treatment news, 2019 was a year of tremendous progress! Because of the complexity of lupus, drug research and development can be especially challenging. The designation was based on the Phase II NOBILITY study, in which the drug in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrated enhanced efficacy compared to Sep 18, 2019 · September 18, 2019 The LRA is pleased to share that the U. Sep 17, 2019 · “New treatment options are needed for lupus nephritis, a potentially life-threatening inflammation of the kidneys that most commonly affects women,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. 4 days ago · Lupus News. The causes of this disease have long been unclear, but now, Northwestern Medicine and Brigham and Women’s Hospital scientists have discovered a molecular defect that promotes the pathologic immune response in lupus and show that reversing this defect may potentially Sep 18, 2019 · This is the 27 th Breakthrough Therapy Designation for Genentech’s portfolio of medicines. Roy, President & CEO of Nov 11, 2019 · AstraZeneca Plc said Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus in a late-stage study. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva ® (obinutuzumab) for adults with lupus nephritis. Sep 18, 2019 · Genentech, a member of the Roche Group, announced that the U. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, a major morbidity of systemic lupus erythematosus (SLE). Sep 19, 2019 · Roche has announced that Gazyva (obinutuzumab) has received US Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. Aug 12, 2021 · Home | News & events | Latest news | Lupus drug breakthrough provides light at the end of the tunnel Lupus drug breakthrough provides light at the end of the tunnel 12 August 2021 On 2 August, 2021, the US Food and Drug Administration (FDA) approved a new drug, anifrolumab, for the treatment of systemic lupus erythematosus (SLE, or lupus). S. This designation was granted based on data from the phase II NOBILITY study in adult patients with proliferative lupus nephritis which showed Gazyva, in Jul 10, 2024 · The autoimmune disease systemic lupus erythematosus — known as lupus — affects more than 1. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. Read the latest research on lupus and related autoimmune diseases, including new experimental treatments. Sep 20, 2019 · Roche announced this week that the U. Basel, 18 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.